Given that cancer vaccine-based immunotherapy may overcome the resistance of PDA to immune checkpoint inhibitors, while immune checkpoint inhibitors may enhance the efficacy of the cancer-vaccine therapies, combining vaccine therapy with dual blockade of CTLA-4 and PD-1 might be an attractive approach, although the autoimmune toxicities can be concern. Here, CTLA4 is linked to cancer.